Iovance Biotherapeutics vs Keros Therapeutics
Iovance Biotherapeutics reported revenue of $264 million in fiscal 2025, about the same as Keros Therapeutics' $244 million in fiscal 2025. Iovance Biotherapeutics had an operating margin of -153.1%, against 27.7% at Keros Therapeutics. Free cash flow was −$336 million at Iovance Biotherapeutics and $106 million at Keros Therapeutics.
Side by side
| Iovance Biotherapeutics | Keros Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $264M | $244M |
| Revenue growth | 60.6% | — |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 34.3% | — |
| Operating margin | −153.1% | 27.7% |
| Net margin | −148.4% | 35.7% |
| Free cash flow | −$336M | $106M |
| Free cash flow margin | −127.6% | 43.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $375M |
| Change in diluted share count | 23.3% | 1.1% |
| Last close | $7.31 | $11.39 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $75,770, sold $506,996 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Iovance BiotherapeuticsKeros Therapeutics
Operating margin
Percent of revenue
Iovance BiotherapeuticsKeros Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Iovance BiotherapeuticsKeros Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Iovance Biotherapeutics and Keros Therapeutics pages.